Sorrento Therapeutics Inc (SRNE)
0.02
0.00 (0.00%)
USD |
OTCM |
Apr 24, 15:59
Sorrento Therapeutics Gross Profit Margin (Quarterly): 43.74% for June 30, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 43.74% |
| March 31, 2023 | 68.09% |
| December 31, 2022 | 12.00% |
| September 30, 2022 | 52.48% |
| June 30, 2022 | 50.23% |
| March 31, 2022 | 68.68% |
| December 31, 2021 | 76.01% |
| September 30, 2021 | 71.92% |
| June 30, 2021 | 76.90% |
| March 31, 2021 | 76.25% |
| December 31, 2020 | 77.57% |
| September 30, 2020 | 77.27% |
| June 30, 2020 | 75.03% |
| March 31, 2020 | 68.41% |
| December 31, 2019 | 89.09% |
| September 30, 2019 | 9.55% |
| June 30, 2019 | 49.34% |
| March 31, 2019 | 62.43% |
| December 31, 2018 | 66.16% |
| September 30, 2018 | 46.97% |
| Date | Value |
|---|---|
| June 30, 2018 | 68.67% |
| March 31, 2018 | 79.01% |
| December 31, 2017 | 95.20% |
| September 30, 2017 | 99.11% |
| June 30, 2017 | 82.51% |
| March 31, 2017 | 78.17% |
| December 31, 2016 | |
| September 30, 2016 | 81.36% |
| June 30, 2016 | 67.29% |
| March 31, 2016 | 63.66% |
| December 31, 2015 | 60.88% |
| September 30, 2015 | 45.24% |
| June 30, 2015 | 73.23% |
| March 31, 2015 | 47.90% |
| December 31, 2014 | 44.49% |
| September 30, 2014 | 58.70% |
| June 30, 2014 | 34.19% |
| March 31, 2014 | 42.32% |
| December 31, 2013 | 96.04% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
9.55%
Minimum
Sep 2019
89.09%
Maximum
Dec 2019
61.33%
Average
68.68%
Median
Mar 2022
Gross Profit Margin (Quarterly) Benchmarks
| Scilex Holding Co | 66.42% |
| AIM ImmunoTech Inc | 81.54% |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 15.54% |
| Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -103.9% |
| Return on Invested Capital | -794.4% |
| Profit Margin (Quarterly) | -633.7% |
| Operating Margin (Quarterly) | -510.9% |
| Return on Net Operating Assets | -136.1% |